BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
48 hedge funds and large institutions have $4.09M invested in BRAINSTORM CELL THERAPUTC in 2024 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 6 closing their positions.
86% more capital invested
Capital invested by funds: $2.19M → $4.09M (+$1.9M)
67% more call options, than puts
Call options by funds: $72K | Put options by funds: $43K
44% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 9
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
2% more funds holding
Funds holding: 47 → 48 (+1)
0.61% more ownership
Funds ownership: 0.55% → 1.16% (+0.61%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$3.96M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$63.6K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$54.8K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$51K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$37.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$63K |
| 2 |
BlackRock
New York
|
-$51.4K |
| 3 |
KWA
Kingswood Wealth Advisors
San Diego,
California
|
-$45.8K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$13.3K |
| 5 |
SFG
Socha Financial Group
Corning,
New York
|
-$6.99K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CCMW
51
Cypress Capital Management (Wyoming)
Sheridan,
Wyoming
| – | -$5.65K | -667 | Closed |
|
|
CA
52
CoreCap Advisors
Southfield,
Michigan
| – | -$75 | -9 | Closed |
|
53
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$105 | +14 | +67% |
|
BCLI Hedge Fund Activity: Q2 2024 in Review
48 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q2 2024, worth a combined $4.09M — up 86% from $2.19M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BCLI positions and 6 closed out — a net gain of 1 holder — while 13 added to existing stakes and 9 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $3.96M. The largest seller was GSA Capital Partners, exiting entirely with an estimated $63K sold.
- 48 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q2 2024, up from 47 in Q1 2024.
- Funds reported $4.09M of BRAINSTORM CELL THERAPUTC stock for Q2 2024, up 86% quarter-over-quarter.
- 7 funds opened new BRAINSTORM CELL THERAPUTC positions in Q2 2024 and 6 closed out, a net change of +1 holder.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q2 2024 was Armistice Capital, an estimated $3.96M added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q2 2024 was GSA Capital Partners, an estimated $63K sold.
Based on aggregated 13F filings for Q2 2024.